U.S. General Merchandise and Department Stores Stock News

In late June 2026, Establishment Labs Holdings Inc. was added to a broad suite of Russell indexes, including the Russell 2000, Russell 3000, and several related growth and small-cap benchmarks, and also appointed veteran healthcare executive and former Cutera CEO Taylor Harris to its Board and key board committees. Harris’s track record in corporate finance, acquisitions, and medtech leadership, combined with the company’s new presence across multiple Russell indexes, could reshape how both...

Big pharma is funding a field it once dismissed. These three psychedelic stocks carry possible clinical catalysts as the healthcare industry turns to alternative medicines.

Billions in prepaid spending flow through this corner of the market every year. Here are three US small-cap stocks positioned to capture it.

Recent commentary from Artisan Partners on slowing growth and a softer outlook for Gartner (IT), together with Russell index rebalancing that moved the stock from large cap to mid cap benchmarks, has sharpened investor focus. See our latest analysis for Gartner. Recent index changes and growth concerns have coincided with weaker momentum in Gartner’s share price. It is down 15.7% on a 30 day basis and 44.0% year to date, while the 1 year total shareholder return has declined 65.8%, pointing...

Axogen (AXGN) has been removed from several Russell indexes, including the Russell Microcap Index and Russell 3000E Index. This change can reshape trading patterns as index funds and passive vehicles rebalance their holdings. See our latest analysis for Axogen. Against the backdrop of these index removals, Axogen’s recent trading has been mixed in the very short term but strong over longer periods. The company has a 1-day share price return of 2.04% and a 90-day share price return of 36.48%,...

In late June 2026, Spyre Therapeutics, Inc. (NasdaqGS: SYRE) was removed from several Russell indices, including the Russell 2000 Value, 2500 Value, 3000 Value, 3000E Value, and Small Cap Comp Value benchmarks. This broad index exclusion matters because many passive and benchmark-aware investors adjust their holdings around such reconstitutions, potentially altering trading patterns and liquidity for the stock. Next, we will examine how this broad Russell index removal shapes Spyre...

In late June 2026, BioAge Labs, Inc. (NasdaqGS:BIOA) was added to multiple Russell Growth Benchmark Indexes, including the Russell 2000, Russell 2500, Russell 3000, Russell 3000E, Russell Microcap, and the Russell Small Cap Comp Growth indexes. This broad index inclusion significantly expands BioAge Labs’ visibility among institutional investors and index-tracking funds that follow these Russell Growth benchmarks. Next, we’ll examine how BioAge Labs’ broad Russell Growth index inclusion...

Index changes put Birkenstock Holding in focus Birkenstock Holding (BIRK) has been removed from several Russell growth benchmarks, a shift that can trigger portfolio rebalancing by index-tracking funds and influence short term trading in the stock. See our latest analysis for Birkenstock Holding. Against this backdrop, Birkenstock Holding’s share price has moved to US$45.32, with a 1 day share price return of 2.44% and a 90 day share price return of 19.17%, while the 1 year total shareholder...

Why Marzetti Stock Is Back on Investors’ Radar Marzetti (MZTI) has attracted fresh attention after being added to several Russell value indices, a change that can affect how many index funds and benchmarked portfolios hold the stock. See our latest analysis for Marzetti. Despite its index additions and the appointment of a new Chief Supply Chain Officer, Marzetti’s short term share price return has been mixed. The stock is down year to date and the 1 year total shareholder return has also...

On 27 June 2026, Golar LNG Limited was added to both the Russell 2000 Value-Defensive Index and the Russell 2000 Defensive Index, expanding its presence in key US equity benchmarks. This dual inclusion could increase the company’s visibility among institutional investors and index-tracking funds that focus on defensive and value-oriented exposures. We’ll now examine how Golar LNG’s entry into these Russell 2000 defensive indexes may influence its existing long-term FLNG investment...

Tariff headlines are back in focus, and this time the pressure is squarely on import costs for U.S. consumers and businesses. With Virginia and other states pushing back against broad U.S. tariffs, investors are weighing what heavier trade frictions and higher prices could mean for different parts of the market. Domestic focused stocks that rely less on imported inputs can appear relatively insulated when trade tensions rise, while others may face higher cost pressure or sentiment swings...

In late June 2026, Oruka Therapeutics, Inc. was removed from several Russell value and microcap indices and simultaneously added to multiple Russell growth benchmarks, including the Russell 2000 and Russell 3000 growth indices. This shift effectively reclassifies Oruka Therapeutics in major index frameworks from a value- and microcap-oriented profile toward a growth-focused small-cap identity, which can materially influence how institutional investors and index-tracking funds view the...

In late June 2026, National HealthCare Corporation amended its credit agreement with Bank of America, expanding its senior unsecured revolving credit facility from US$50,000,000 to US$75,000,000 and drawing US$475,000,000 under a term loan plus US$55,000,000 under the revolver to help fund a transaction. Around the same time, National HealthCare was added to several Russell growth and small-cap benchmarks, a change that can increase its visibility with index-tracking funds and institutional...

In recent days, First Industrial Realty Trust reported strong Q1 2026 results, with earnings per share of US$1.08 significantly exceeding forecasts, and attracted renewed coverage from several investment firms highlighting demand for its logistics properties. This combination of outperformance against expectations and fresh analyst attention has sharpened the focus on how First Industrial is positioned within the industrial real estate market. With Q1 earnings materially ahead of forecasts,...

Fitzroy Island Resort recently announced it has replaced a fragmented set of legacy hospitality systems with a unified Agilysys platform, cutting night audit workloads in half and automating key financial reporting tasks. Staff adoption has been so strong that employees resisted any rollback to the old software, while the resort now also uses Agilysys Book and Reserve to track Great Barrier Reef visitor metrics and coordinate conservation-related travel. We’ll now examine how this rapid,...

Recently, Nutex Health Inc. announced that its microhospital model, which makes extensive use of No Surprises Act arbitration, has helped drive revenue to roughly triple and profits to grow by a very large multiple. This approach shifts the company’s core economics toward reimbursement outcomes and payer disputes, making arbitration performance almost as important as patient volumes or new facility openings. Next, we’ll examine how Nutex’s arbitration-driven microhospital success reshapes...

Royalty Pharma plc (NasdaqGS:RPRX) was added to both the Russell 1000 Value-Defensive Index and the Russell 1000 Defensive Index on 27 June 2026, highlighting its classification among larger, relatively more defensive US equities. This dual index inclusion can raise Royalty Pharma’s visibility with institutional investors and index-tracking funds, potentially increasing demand for its shares and reinforcing its profile as a defensive healthcare royalty specialist. Next, we’ll examine how...

Pure Cycle (PCYO) has posted its Q3 2026 numbers with total revenue of about US$8.2 million and basic EPS of US$0.12, set against trailing twelve month revenue of roughly US$33.7 million and EPS of US$0.61, underpinned by 8.2% earnings growth over the past year. Over recent quarters, the company has seen revenue move from around US$5.2 million with EPS of US$0.03 in Q2 2025 to US$11.2 million with EPS of US$0.25 in Q4 2025, then to US$8.2 million and EPS of US$0.12 in Q3 2026. This has left...

Butler National (BUKS) has put up a clean set of FY 2026 numbers, with fourth quarter revenue at US$27.7 million and basic EPS of US$0.09, alongside trailing twelve month revenue of US$98.0 million and EPS of US$0.34 that sit against reported earnings growth of 74.8% over the past year. Over recent periods the company has seen revenue progress from US$83.97 million on a trailing basis in FY 2025 to US$98.0 million in FY 2026. EPS over the same trailing window moved from US$0.19 to US$0.34,...

Wayfair's share price has rebounded in the last year, but with the stock still down 68.5% over five years and screening as overvalued on market multiples, the current level raises questions about how much of the recovery story is already reflected in the price. Over the past five years, Wayfair has delivered a total return that is down 68.5%, which highlights how deep the earlier drawdown was despite the more recent strength. Recent optimism around improving earnings expectations can support...

PriceSmart (PSMT) has released its Q3 2026 results, reporting revenue of about US$1.5b, basic EPS of roughly US$1.31 and net income, excluding extra items, of US$39.7m. The company’s quarterly revenue has moved from US$1.33b in Q4 2025 to US$1.38b in Q1 2026, US$1.50b in Q2 2026 and US$1.48b in Q3 2026. Over the same period, basic EPS ranged from US$1.02 to US$1.62, giving investors a clear view of top line scale and earnings power to track. With trailing 12 month EPS of about US$5.22 and a...

Clinical momentum and index changes frame Dianthus Therapeutics stock story Dianthus Therapeutics (DNTH) has kicked off its global Phase 3 EMERGE trial for claseprubart in generalized Myasthenia Gravis, while the stock was recently removed from several Russell value and growth benchmarks. The EMERGE trial will enroll about 195 acetylcholine receptor antibody positive generalized Myasthenia Gravis participants and compare subcutaneous claseprubart against placebo, with the Myasthenia Gravis...

Arbutus Biopharma stock has delivered a strong 126.4% return over the past three years, yet its current valuation checks and market multiples suggest the shares are not a clear bargain at recent levels. Over the last three years, Arbutus Biopharma has returned 126.4%, which puts extra focus on whether the current share price already reflects much of the good news investors are hoping for. Expectations around the company’s ability to turn its pipeline and research into durable cash flows can...

AZZ (AZZ) has opened fiscal 2027 with Q1 revenue of $448.5 million and basic EPS of $1.74, setting the tone for how its earnings story is evolving after a mixed year of growth and margin shifts. The company has seen quarterly revenue move from $421.9 million and EPS of $5.71 in Q1 2026 to $448.5 million and $1.74 in Q1 2027, against a backdrop where trailing 12 month EPS was $6.62 and net income was $198.4 million. This frames a results season in which investors are watching how profit...